BridgeBio Pharma Long Term Debt 2018-2023 | BBIO
BridgeBio Pharma long term debt from 2018 to 2023. Long term debt can be defined as the sum of all long term debt fields.
- BridgeBio Pharma long term debt for the quarter ending December 31, 2023 was $1.727B, a 1.12% increase year-over-year.
- BridgeBio Pharma long term debt for 2023 was $1.727B, a 1.12% increase from 2022.
- BridgeBio Pharma long term debt for 2022 was $1.708B, a 0.22% increase from 2021.
- BridgeBio Pharma long term debt for 2021 was $1.704B, a 258.05% increase from 2020.
BridgeBio Pharma Annual Long Term Debt
(Millions of US $) |
| 2023 |
$1,727 |
| 2022 |
$1,708 |
| 2021 |
$1,704 |
| 2020 |
$476 |
| 2019 |
$92 |
| 2018 |
$55 |
| 2017 |
$ |
BridgeBio Pharma Quarterly Long Term Debt
(Millions of US $) |
| 2023-12-31 |
$1,727 |
| 2023-09-30 |
$1,721 |
| 2023-06-30 |
$1,719 |
| 2023-03-31 |
$1,713 |
| 2022-12-31 |
$1,708 |
| 2022-09-30 |
$1,699 |
| 2022-06-30 |
$1,693 |
| 2022-03-31 |
$1,708 |
| 2021-12-31 |
$1,704 |
| 2021-09-30 |
$1,375 |
| 2021-06-30 |
$1,374 |
| 2021-03-31 |
$1,361 |
| 2020-12-31 |
$476 |
| 2020-09-30 |
$472 |
| 2020-06-30 |
$467 |
| 2020-03-31 |
$461 |
| 2019-12-31 |
$92 |
| 2019-09-30 |
$75 |
| 2019-06-30 |
|
| 2019-03-31 |
|
| 2018-12-31 |
|
| 2018-09-30 |
|
| 2017-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$5.208B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
